Fluidra and Cellnex are two of the most lagging stocks in the Ibex, despite receiving a high percentage of buy recommendations. Fluidra, with a decline of nearly 23% so far this year, has 83.3% of favourable advice.
In 2026, the Ibex has recorded an increase of over 13%, however, some companies are lagging, with declines ranging from 6% to 23%. According to expansion.com, Fluidra, Amadeus, and Cellnex are the stocks that, despite their decline, receive strong analytical support.
Fluidra is positioned as the most punished stock in the index, with a drop of **23%**. Despite this, it boasts an impressive **83.3%** of buy recommendations and trades at a discount of over **47%** against its twelve-month target price. Firms like UBS and CaixaBank estimate that its value could exceed **30 euros**. Additionally, Fluidra maintains its annual guidance and is conducting a share buyback worth **40 million euros**.
Cellnex, the telecommunications tower operator, also has strong analyst support, with nearly **80%** recommending the purchase of its shares. Although the rise in interest rates may affect its valuation, its high proportion of fixed-rate debt (around **78%**) mitigates this impact. Renta 4 highlights its solid operational growth and the recent increase to one billion euros in shareholder remuneration for 2026.
Amadeus, despite doubts about the impact of artificial intelligence on its business, is also considered an opportunity. Deutsche Bank has raised its valuation, suggesting that the market is not correctly valuing its position as a leader in the global distribution system.
On the other hand, Inditex has had a more subdued performance, with a decline of **6%** following results that disappointed analysts. However, its upcoming growth plan, which will be presented in March, is expected to generate an increase in its medium-term profit expectations.
You may also like
